Stamford Pharmaceuticals Inc, a clinical stage oncology company with a near-term pipeline focused on cutaneous cancer announced today that it has relocated its head office to Austin Texas to Suite 1900, 500 W, 2ND St. Stamford Pharmaceuticals is currently undertaking a Phase 2 clinical trial evaluating its lead agent SP-002 as a treatment for patients that present with multiple basal cell carcinomas. The study is on-going and is expected to complete in the 1H of 2023. The Company will also commence a second study, a Phase 2b in Locally Advanced Basal Cell Carcinoma in 2H, 2023.

Press Release: Stamford Pharmaceuticals Inc has relocated its head office to Austin Texas